A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model

Molecular Therapy

Volumn 7, Issue 2, 2003, Pages 163-173

  Hemminki, Akseli ^a,b,c   Kanerva, Anna ^a,c   Kremer, Eric J ^d   Bauerschmitz, Gerd J ^a   Smith, Bruce F ^e   Liu, Bin ^a   Wang, Minghui ^a   Desmond, Renee A ^f   Keriel, Anne ^d   Barnett, Brian ^a   Baker, Henry J ^e   Siegal, Gene P ^a,g   Curiel, David T ^a  

^a University of Alabama at Birmingham   (United States)

^b and Radiation Oncology   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^e AUBURN UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

Adenovirus; Biological therapy; Dogs; Gene therapy; Humans; Immunosuppressive agents; Neoplasms; Osteocalcin; Osteosarcoma; Virus replication

Indexed keywords

DILUENT; IMMUNOMODULATING AGENT; ONCOLYTIC VIRUS; OSTEOCALCIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL DESTRUCTION; CANCER THERAPY; CLINICAL STUDY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FREQUENCY ANALYSIS; HUMAN; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROMOTER REGION; SEROTYPE; TREATMENT OUTCOME; TUMOR RESISTANCE; UNITED STATES; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; CANINE ADENOVIRUS; CANIS FAMILIARIS;

EID: 0037301795     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00049-7     Document Type: Article

References (50)

1. Hemminki, A., and Alvarez, R. D. (2002). Adenoviruses in oncology: a viable option? BioDrugs 16: 77-87.
2. Bauerschmitz, G. J., Barker, S. D., and Hemminki, A. (2002). Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agent. Int. J. Oncol. 21: 1161-1174.
3. Nemunaitis, J., et al. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19: 289 -298.
4. Habib, N., et al. (2002). Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 9: 254-259.
5. Khuri, F. R., et al. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6: 879-885.
6. Russell, W. C. (2000). Update on adenovirus and its vectors. J. Gen. Virol. 81: 2573-2604.
7. Hemminki, A., Wang, M., Desmond, R. A., Strong, T. V., Alvarez, R. D., and Curiel, D. T. (2002). Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum. Gene Ther. 13: 1505-1514.
8. Chen, Y., Yu, D. C., Charlton, D., and Henderson, D. R. (2000). Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Ther. 11: 1553-1567.
9. Yoon, S. S., Nakamura, H., Carroll, N. M., Bode, B. P., Chiocca, E. A., and Tanabe, K. K. (2000). An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 14: 301-311.
10. Alemany, R., Balague, C., and Curiel, D. T. (2000). Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18: 723-727.
11. Ganly, I., Mautner, V., and Balmain, A. (2000). Productive replication of human adenoviruses in mouse epidermal cells. J. Virol. 74: 2895-2899.
12. Prince, G. A., Porter, D. D., Jenson, A. B., Horswood, R. L., Chanock, R. M., and Ginsberg, H. S. (1993). Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J. Virol. 67: 101-111.
13. Torres, J. M., Alonso, C., Ortega, A., Mittal, S., Graham, F., and Enjuanes, L. (1996). Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J. Virol. 70: 3770-3780.
14. Rasmussen, U. B., Benchaibi, M., Meyer, V., Schlesinger, Y., and Schughart, K. (1999). Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum. Gene Ther. 10: 2587-2599.
15. Ikeda, K., et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5: 881-887.
16. Halford, W. P., and Schaffer, P. A. (2000). Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants to establish wild-type levels of latency in vivo. J. Virol. 74: 5957-5967.
17. Smith, R. R., Huebner, R. J., Rowe, W. P., Schatten, W. E., and Thomas, L. B. (1956). Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 9: 1211-1218.
18. Faden, H., Jockin, H., Talty, M. R., Fazilli, R., and Barrett, H. (1985). Fatal disseminated adenovirus infection featuring liver necrosis and prolonged viremia in an immunosuppressed child with malignant histiocytosis. Am. J. Pediatr. Hematol. Oncol. 7: 15-20.
19. Hierholzer, J. C. (1992). Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 5: 262-274.
20. Munoz, F. M., Piedra, P. A., and Demmler, G. J. (1998). Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin. Infect. Dis. 27: 1194-1200.
21. Howell, J. M., et al. (1998). High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum. Gene Ther. 9: 629-634.
22. Fang, B., et al. (1995). Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum. Gene Ther. 6: 1039-1044.
23. Elshami, A. A., et al. (1995). The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222: 298-307.
24. Yang, Y., Trinchieri, G., and Wilson, J. M. (1995). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1: 890-893.
25. Kay, M. A., et al. (1997). Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc. Natl. Acad. Sci. USA. 94: 4686-4691.
26. Bouvet, M., et al. (1998). Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58: 2288-2292.
27. Stein, C. S., Pemberton, J. L., van Rooijen, N., and Davidson, B. L. (1998). Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Ther. 5: 431-439.
28. Withrow, S. J., Powers, B. E., Straw, R. C., and Wilkins, R. M. (1991). Comparative aspects of osteosarcoma. Dog versus man. Clin. Orthop. 159-168.
29. Dernell, W. S., Straw, R. C., and Withrow, S. J. (2001). Tumors of the skeletal system. In Small Animal Clinical Oncology (S. J. Withrow and E. G. MacEwen, Eds.), pp. 378-417. Saunders, Philadelphia.
30. Ford, R. B., and Vaden, S. L. (1998). Canine Infectious Tracheobronchitis. Saunders, Philadelphia.
31. Kremer, E. J., Boutin, S., Chillon, M., and Danos, O. (2000). Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J. Virol. 74: 505-512.
32. Soudais, C., et al. (2000). Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway. J. Virol. 74: 10639-10649.
33. Chillon, M., and Kremer, E. J. (2001). Trafficking and propagation of canine adenovirus vectors lacking a known integrin-interacting motif. Hum. Gene Ther. 12: 1815-1823.
34. Soudais, C., Boutin, S., and Kremer, E. J. (2001). Characterization of cis-acting sequences involved in canine adenovirus packaging. Mol. Ther. 3: 631-640.
35. Ko, S. C., et al. (1996). Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 56: 4614-4619.
36. Lian, J. B., Stein, G. S., Stein, J. L., and van Wijnen, A. J. (1998). Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. J. Cell. Biochem. Suppl. 31: 62-72.
37. Koeneman, K. S., et al. (2000). Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18: 102-110.
38. Wu, T. T., et al. (1998). Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer. 77: 887-894.
39. Kanerva, A., et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5: 695-704.
40. Fleet, J. C., and Hock, J. M. (1994). Identification of osteocalcin mRNA in nonsteroid tissue of rats and humans by reverse transcription-polymerase chain reaction. J. Bone Miner. Res. 9: 1565-1573.
41. Cheon, J., et al. (1997). Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 4: 359-365.
42. Shirakawa, T., et al. (1998). In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 5: 274-280.
43. Yu, D. C., Chen, Y., Seng, M., Dilley, J., and Henderson, D. R. (1999). The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59: 4200-4203.
44. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W. and Henderson, D. R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2359-2563.
45. Hallenbeck, P. L., et al. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10: 1721-1733.
46. Kurihara, T., Brough, D. E., Kovesdi, I., and Kufe, D. W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106: 763-771.
47. Hortobagyi, G. N., et al. (2001). Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J. Clin. Oncol. 19: 3422-3433.
48. MacEwen, E. G., and Rosenthal, R. C. (1989). Approach to treatment of cancer patients. In Textbook of Veterinary Internal Medicine (S. J. Ettinger, Ed.), pp. 527-546. Saunders, Philadelphia.
49. Weiser, M. G. (1989). Erythrocytes and associated diseases. In Textbook of Veterinary Internal Medicine (S. J. Ettinger, Ed.), pp. 2145-2180. Saunders, Philadelphia.
50. Hemminki, A., et al. (2001). An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. 4: 223-231.